Rising China Payer Agency Screaming For Drug Cost Control
This article was originally published in PharmAsia News
Executive Summary
The supervision over medical costs in China is set to tighten with closer scrutiny of physicians’ practices, while analysts are advising multinational drug makers to consider other options for reimbursement listing than the national list.